Related Experiment Video

Updated: Aug 9, 2026

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Targeting the ubiquitin-proteasome pathway in breast cancer therapy

E Claire Dees1, Robert Z Orlowski

  • 1Department of Medicine, Division of Hematology/Oncology & Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA.

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

The ubiquitin-proteasome pathway (UPP) is crucial for cell protein breakdown. While UPP inhibitors work in blood cancers, their role in breast cancer therapy is emerging, offering new strategies to improve chemotherapy effectiveness.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The ubiquitin-proteasome pathway (UPP) is the primary mechanism for regulated intracellular proteolysis in eukaryotes.
  • Proteasome inhibitors are effective against hematologic malignancies but show limited activity in solid tumors like breast cancer.
  • Dysregulation of the UPP is increasingly implicated in mammary tumorigenesis.

Purpose of the Study:

  • To review the biology of the UPP and its role in breast cancer.
  • To summarize current knowledge on clinical proteasome and heat shock protein inhibition.
  • To explore future therapeutic strategies targeting the UPP in breast cancer.

Main Methods:

  • Literature review of UPP biology and its role in cancer.
  • Analysis of clinical trial data for proteasome inhibitors in solid tumors.
  • Discussion of emerging therapeutic approaches and future research directions.

Main Results:

  • UPP dysregulation is significant in breast cancer development.
  • Modulating UPP function may enhance chemosensitivity and overcome resistance.
  • Clinical application of UPP inhibitors in breast cancer is still developing.

Conclusions:

  • The UPP is a promising therapeutic target for breast cancer.
  • Further research is needed to optimize UPP-targeted therapies for solid tumors.
  • Exploiting the UPP pathway holds potential for improving breast cancer treatment outcomes.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...